Fernando Sallés

🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!

3

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update   Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), a clinical stage #biopharmaceutical company focused on developing new #antibiotics for difficult-to-treat #bacterial infections, has announced a conference call to discuss its second quarter 2024 financial results. The call is scheduled for August 9, 2024, at 8:00 am ET, before the U.S. financial markets open.   The company's President and CEO, David Luci, along with CFO Robert Shawah, will host the call to present the #financial results and provide a business update. #Investors and interested parties can join the call using the provided toll-free number for U.S. participants or international access numbers.   https://lnkd.in/esMuCywW #nasdaq #acxp #antibiotics #acurx Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) David Luci

14

CDMOs eye industrywide growth in 2025 as many spurn BIOSECURE Act, CPHI research shows - Fierce Pharma After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound in 2025. That's according to new research from CPHI Milan ahead of the group's manufacturing conference next month. As it stands, 49% of the CDMO industry is “highly positive” on contract services growth in the next 18 months, CPHI said in a release, citing new research pooling insights from 280 pharma companies. The optimistic mood comes despite an uneven recovery in the biopharma industry after the pandemic. While funding has flowed to later-stage projects, early-stage assets continue to face a funding deficit, Gil Roth, president of the Pharma & Biopharma Outsourcing Association said in a statement. “This means that the lifeblood of CDMOs—projects moving through the development pipeline and smaller customers sticking with key service providers—remains hobbled,” Roth said. https://lnkd.in/eegVNZKf

4

#BigPharma's growing interest in the #cellandgenetherapy space has the potential to reshape the industry's future. At this year's Cell & Gene #MeetingontheMesa, industry leaders highlighted that large pharma companies' significant resources and expertise are uniquely positioned to address the complex challenges of developing and commercializing these therapies. From high #manufacturing costs to navigating #regulatory hurdles, Big Pharma is playing an essential role in scaling innovations that smaller biotechs often struggle to bring to market. Their partnerships will prove critical to bringing life saving treatments to patients who need them most. As the sector continues to evolve, collaboration between Big Pharma and biotech can help shape the future of cell and gene therapies.

49

1 Comment

Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules   Acurx Pharmaceuticals, Inc. (#NASDAQ: #ACXP), a late-stage #biopharmaceutical company developing a new class of #antibiotics for difficult-to-treat #bacterial #infections, announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,463,058 shares of its common stock at a purchase price of $1.015 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,463,058 shares of common stock. The warrants will have an exercise price of $0.90 per share, will be exercisable upon issuance and expire five years following the date of issuance. The closing of the offering is expected to occur on or about January 7, 2025, subject to the satisfaction of customary closing conditions.   https://lnkd.in/eAKy4iSM #nasdaq #acxp #antibiotics #acurx

18

1 Comment

Want glycan analysis method expertise? In this video, our Navin Rauniyar discusses his recently published study. Check it out! #proteinsciences #protein #groundbreaking #biotech #CDMO #analyticaldevelopment #glycananalysis

42

Add more quantifiable data revvvvvv your AI engine!!!! Not just binding and sequences… add color to your data to tremendously increase your algo’s prediction power! Only on the #Beacon #optofluidic platform

19

Why Gilead Sciences and Arcellx Anito-cel's data shows Promise in Multiple Myeloma Therapy Innovative Safety Profile: Early clinical data suggest anito-cel offers a reassuring safety advantage, with no reported cases of Parkinsonism, cranial nerve palsies, or Guillain-Barré syndrome—potentially addressing critical quality-of-life concerns. Encouraging Efficacy: With a 97% response rate and a median progression-free survival of 30.2 months in Phase 1, anito-cel demonstrates strong potential as an effective treatment option in heavily pretreated multiple myeloma patients. Cutting-Edge Technology: Anito-cel’s unique D-Domain binding technology may contribute to its promising safety and efficacy, reflecting innovation in CAR-T therapy design. #CellTherapy #MultipleMyeloma #InnovationInHealthcare #CAR_T #advancedtherapies #biotech #biotechnology #lifesciences #Data #ASH2024 https://lnkd.in/eCmJ_vP3

26

EPFL: Unexpected immune response may hold key to long-term cancer remission Results from a preclinical study in mice, led by EPFL, and a collaborative clinical study in patients show that the type 2 immune response – associated with parasitic infection and thought to play a negative role in cancer immunity – is positively correlated with long-term cancer remission. In 2012, 7-year-old Emily Whitehead became the first pediatric patient to receive pioneering chimeric antigen receptor (CAR-T) therapy to fight the recurrence of acute lymphoblastic leukemia (ALL). Twelve years later, Emily is in remission and a student at the University of Pennsylvania, where the therapy was developed. But for many others, the fight continues: more than half of ALL patients experience a relapse within one year following CAR-T therapy. Now, samples from the same pioneering clinical trials have been used in a new study, recently published in Nature in collaboration with EPFL, Yale University, University of Pennsylvania and Cleveland Clinic, that could again signal a paradigm shift in cancer treatment. “For this study, the goal was to determine if the CAR-T cells of long-surviving ALL patients like Emily had a certain profile, or signature, that distinguished them from patients who relapsed,” explains Li Tang, head of the Laboratory of Biomaterials for Immunoengineering in EPFL’s School of Engineering. In CAR-T therapy, white blood cells called T cells are extracted and engineered to express certain proteins that better target a patient’s cancer. The modified CAR-T cells are then transferred back to the patient, with some retained for research. For the Nature study, scientists used nearly 700,000 CAR-T cells from 82 ALL patients, plus six healthy controls, and created a gene expression atlas to analyze each individual cell. This atlas showed that the cells of long-term ALL survivors indeed had something special: they contained certain proteins – notably the cytokine IL-4, among others – usually associated with something called a type 2 immune response. https://lnkd.in/eXA8vd-t Nature: https://lnkd.in/eywpzHHC

41

4 Comments

Vertex Pharmaceuticals Expands in vivo Gene Editing Delivery Horizon with Orna Therapeutics Partnership Strategic Collaboration: Vertex has entered a three-year agreement with Orna Therapeutics to leverage Orna’s lipid nanoparticles (LNPs) for in vivo delivery of gene editors, targeting advancements in treatments for sickle cell disease and beta thalassemia. Unlike existing therapies like Casgevy, this approach aims to eliminate the need for ex vivo cell editing and complex chemotherapy conditioning. Financial Details: The deal includes an upfront payment of $65 million (partially as a convertible note), with Orna eligible for up to $635 million in milestones for the sickle cell and thalassemia programs and an additional $365 million for up to 10 other indications. Tiered royalties on potential products are also part of the agreement. Long-Term Impact: This in vivo gene editing strategy could simplify manufacturing, increase accessibility, and potentially provide a more patient-friendly alternative to existing therapies, which currently reach only a fraction of those in need. #65mupfront #635milestones #365madditional #funding #financing #cellandgenetherapy #invivo #geneediting #sicklecell #thalassemia #raredisease #biotech #biotechnology #lifesciences #patientaccess #LNP

90

1 Comment

💡 Maximizing Performance in Microplate Shaking: Understanding the Limits of 3mm Incubator Shakers 💡 3mm orbit incubator shakers have been the biggest trend in shaking in the past 5 years with some papers claiming (multiple fold in some cases) increases in Viable Cell Densities (VCDs) and product titers when shaking 1ml of culture volume in 96DW blocks at 3mm/1000rpm versus 50mm/300rpm. When working with incubator shakers, especially those with a 3mm shaking orbit, it's essential to match the equipment to the task at hand. These shakers are great for specific applications but come with limitations that can affect experimental outcomes if not understood. 🔬 Optimal Use for 96-Deepwell Plates 3mm orbit shakers are well-suited for larger filling volume cultures in 96-deepwell plates. The small shaking orbit aligns with the dimensions and geometry of these plates, ensuring proper mixing, phase alignment, and oxygen transfer rates (OTR/kLa) of cultures op to 1ml. ❌ Why They Fall Short with 24-Deepwell Plates Due to the larger diameter of a well of a 24-deepwell plate, the speed of the liquid cannot keep up with shaker speed resulting in an out of phase condition. This can be seen in the video below and will lead to: - Inadequate mixing, leaving dead zones in the wells. - Poor oxygen transfer efficiency (low OTR/kLa values). - Splashing and formation of aerosols. - Suboptimal growth or reaction conditions, leading to inconsistent or poor results. ⚠️ The Lesson: Not all shakers are created equal for every plate type. Matching your equipment to your experimental setup is critical for reproducibility and success. If you're using 24-deepwell plates, use shakers with a larger orbit, better suited to these plate dimensions. 3mm shakers are trendy, 50mm shakers are forever! #LabTips #ShakingOrbit #OTR #DeepwellPlates #Biotechnology #CHO #HEK #CellCulture

32

3 Comments

New Patent Alert! We’re proud to announce that GenNext Technologies has received its fourth and fifth United States Patent! One protects an exciting and proprietary means by which Fox® Protein Footprinting is combined with in-line molecular separation, such as liquid chromatography, to separate and individually label heterogeneous samples, comprising mixed conformers, multi-unit protein complexes, or other diverse protein populations. The other protects the company’s exclusive means and methods by which robust and reproducible in-cell radical protein footprinting studies are performed. These two new patents further establish GenNext as the pre-eminent company in high-resolution protein footprinting, enabling researchers to develop safer, more effective, and more affordable therapeutics. A heartfelt thank you to our dedicated GenNext Team for your relentless effort and innovation in advancing the field of structural biology research! #GenNext #Research #Science #ScientificResearch #Biotherapeutics #ProteinCharacterization #ResearchInnovation #HRPF #ProteinResearch #ScientificInnovation #Teamwork #ProteinStructure #StructuralBiology #Biochemistry #Proteomics #Biotechnology #Antibody #mAb

32

3 Comments

Elevation Oncology Partners with Synaffix BV in $368M Deal to Advance HER3 ADC Development Synaffix announces that it has entered into a licensing agreement with Elevation Oncology to develop EO-1022, a HER3-targeting Antibody-Drug Conjugate (ADC) leveraging Synaffix’s advanced platform technologies. This collaboration aims to create a highly effective and safer therapy for HER3-positive solid tumors. With up to $368 million in milestone payments, this partnership highlights the transformative potential of ADCs in precision oncology and patient care. Cutting-Edge Technology Integration Synaffix provides Elevation Oncology with global access to its clinical-stage, site-specific ADC technology platform, including GlycoConnect® antibody conjugation, HydraSpace® polar spacer, and the toxSYN® linker-payload SYNstatin E™. These advanced technologies enable the creation of a differentiated HER3 ADC candidate with enhanced efficacy and tolerability, holding the potential to set a new benchmark in oncology therapeutics. Strategic and Financial Framework Under the agreement terms, Synaffix will receive up to $368 million, contingent on achieving specific clinical, regulatory, and commercial milestones. Additionally, Elevation Oncology will handle research, development, and commercialization, while Synaffix will manage manufacturing components tied to its proprietary platform. https://lnkd.in/em89DTzB

19

1 Comment

Engineered CD47 protects T cells for enhanced antitumour immunity Adoptively transferred T cells and agents designed to block the CD47–SIRPα axis are promising cancer therapeutics that activate distinct arms of the immune system1,2. Here we administered anti-CD47 antibodies in combination with adoptively transferred T cells with the goal of enhancing antitumour efficacy but observed abrogated therapeutic benefit due to rapid macrophage-mediated clearance of T cells expressing chimeric antigen receptors (CARs) or engineered T cell receptors. Anti-CD47-antibody-mediated CAR T cell clearance was potent and rapid enough to serve as an effective safety switch. To overcome this challenge, we engineered the CD47 variant CD47(Q31P) (47E), which engages SIRPα and provides a ‘don’t eat me’ signal that is not blocked by anti-CD47 antibodies. TCR or CAR T cells expressing 47E are resistant to clearance by macrophages after treatment with anti-CD47 antibodies, and mediate substantial, sustained macrophage recruitment to the tumour microenvironment. Although many of the recruited macrophages manifested an M2-like profile3, the combined therapy synergistically enhanced antitumour efficacy. Our study identifies macrophages as major regulators of T cell persistence and illustrates the fundamental challenge of combining T-cell-directed therapeutics with those designed to activate macrophages. It delivers a therapeutic approach that is capable of simultaneously harnessing the antitumour effects of T cells and macrophages, offering enhanced potency against solid tumours. https://lnkd.in/eUsVmmw2

30

University of Pennsylvania spinout Interius BioTherapeutics raises $67M in a private equity round. The Philadelphia company is seeking to raise a total of $82.5 million from its Series B round. July 9, 2024 Interius was granted Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to commence a first-in-human Phase 1 clinical trial of INT2104, its lead in vivo CAR candidate for treatment of B-cell malignancies. #funding #financing #genetherapy #invivo #CARtherapy #therapeutics #Bcellmalignancies #celltherapy #genetherapy #advancedtherapies #regenerativemedicine #lifescience #lifesciences #biotech #biotechnology #clinicaltrials #seriesfinancing #equityfinancing

114

3 Comments

UPDATED: December 11 and 12, 2024 headlines from the Collabrity Report, a daily summary of financings for therapeutic biotechnology company executives and investors - www.collabrityreport.com New! Collabrity Report (CR) Analytics Acadia’s $150 Million Asset Sale Angitia’s $120 Million Series C ImmunityBio’s $100 Million Public Offering Candel’s $80 Million Public Offering Veradermics’s $75 Million Series B Chroma’s $75 Million Merger with Nvelop Cellectis’s $41 Million Debt Financing Scilex’s $17 Million Registered Direct Offering Alessa’s $15 Million Seed Round CG’s $7 Million Public Offering BriaCell’s $6 Million Public Offering Aptevo’s $6 Million Warrant Exercise Palisade’s $5 Million Public Offering Okogen’s $3 Million Series B

2

CicrRNA 2.0. This paper from the Wang lab @ MIT finds that a branched mRNA cap effectively initiates translation on linear or circular #mRNAs without IRES. Two types of chemical modification, locked nucleic acid (LNA) N7-methylguanosine modifications on the cap and LNA + 5 × 2′ O-methyl on the 5′ untranslated region, enhance RNA–eukaryotic translation initiation factor (eIF4E–eIF4G) binding and RNA stability against decapping in vitro. Through multidimensional chemotopological engineering of dual-capped mRNA and capped circular RNA, we enhanced mRNA protein production by up to tenfold in vivo, resulting in 17-fold and 3.7-fold higher antibody production after prime and boost doses in a severe acute respiratory syndrome coronavirus 2 vaccine setting, respectively.  https://lnkd.in/eX2a9Tn3

105

1 Comment

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference   • Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including increased relative proportion of Actinobacteria in ibezapolstat-treated patients with C. difficile Infection (CDI) • Results consistent with those shown in earlier human volunteer studies and Phase 2a studies • Preservation and increased concentrations of beneficial Firmicute (Bacilotta) phylum known to be involved in bile acid homeostasis and short chain fatty acid metabolism was demonstrated  • Actinobacteria and Bacteroides preservation also confirmed using quantitative analysis   https://lnkd.in/eseFt8GZ   #nasdaq #acxp #antibiotics #acurx Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) David Luci

13

Pharma/Biotech Roundup 🔃 Septerna: Upsized IPO raises $288M to support pipeline of GPCR Drugs Alpha-9 Oncology: Announces $175 Million oversubscribed Series C Financing to advance clinical pipeline of radiopharmaceuticals AvenCell: Raises $112 Million in Series B; Funding led by Novo Holdings Lyell Immunopharma: To acquire ImmPACT Bio and prioritize their pipeline in order to concentrate on next-generation CAR T-cell therapies. Set to discontinue the development of LYL797, LYL845 and earlier-stage TIL programs GSK: Investing up to $800 million to double the size and capacity of its production site in Marietta, Pennsylvania Sanofi: Continuing to move forward to sell a 50% stake in Opella to CD&R Monopar Therapeutics Inc.: Finalizes an agreement with Alexion Pharmaceuticals, Inc. for an exclusive license to ALXN-1840, a drug candidate for Wilson disease Alto Neuroscience: Stock has dropped by over 60% after Phase 2b trial of their lead drug candidate in depression failed to meet primary goals Merck: Acquires Modifi Bio and brain cancer assets for $30M

22